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ers knowledge of ﬁbromyalgia reveals no difference regarding the
deﬁnition of this pathology and some mild differences appears
in their knowledge of the ACR criteria and their appreciation of
the associated symptoms (the frequency of widespread pain and
joint swelling in particular). It is surprising how the knowledge
GPs in France and Portugal have of FM is closer than between
GPs and Rheumatologists in each country.
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OBJECTIVES: To assess the cost-effectiveness of Palivizumab, a
prevention against respiratory syncytial virus (RSV) infections in
infants at high risk, such as premature babies, infants with bron-
chopulmonary dysplasia (BPD), and children with congenital
heart disease (CHD). METHODS: A decision tree model was
used to estimate the cost-effectiveness of Palivizumab in high-
risk children. The data sources included published literature, the
Palivizumab clinical trials, ofﬁcial price/tariff lists and national
population statistics. The primary perspective of the study was
that of the society, which included cost of the complications
asthma and wheezing. RESULTS: The use of Palivizumab results
in an ICER of €12,728/QALY without discounting for effective-
ness, which increases to €20,236/QALY after discounting for
effectiveness in the prematurity/BPD indications. In the CHD
indication the use of Palivizumab results in an ICER of
€4256/QALY without discounting for effectiveness and
€7067/QALY after discounting for effectiveness. Sensitivity
analyses conﬁrmed the robustness of the model. CONCLU-
SION: This study showed that Palivizumab is a cost-effective
treatment against RSV in infants at high risk: the use of
Palivizumab results in positive short and long-term health eco-
nomic beneﬁts to the society and health authorities.
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OBJECTIVE: The objective of the study was the estimation of
the actual hospitalization costs of two neonatal intensive care
units of university of Athens. METHODS: The study was based
on retrospective data gathered from the records of 70 neonates
who were hospitalized at the NICUs of Alexandra’s obstetric and
Aglaia Kyriakou pediatric hospitals of Athens, with admission
dates between February and April 2004 until their discharge
from the hospital. Clinical data derived from medical records,
while economic data from each hospital’s administrative and
ﬁnancial department. Regression analysis was performed with
SPSS program in order to ﬁnd the correlation between the cost
and birthweight and other parameters. The mean daily treatment
cost was estimated according to: birth weight and gestational age
of the neonates as well as Length of Stay in NICU and Interme-
diate level II until their discharge from hospital. Direct cost
analysis was based on cost of personnel, cost of supplies, med-
ication, parental feeding, laboratory and imaging tests, cost of
infrastructure, hotel services and various other on-site costs. The
economic analysis did not include the depreciation of capital
assets. The prices used for the analysis were based on Greek NHS
prices, expressed in €2004. RESULTS: The mean daily actual
cost per infant in the NICU of Alexandra was 207 euro and for
intermediate level II €121. The mean daily actual cost per infant
in NICU for Aglaia Kyriakou hospital was 511€ and for inter-
mediate level II €231. The mean length of stay (LOS) in the
NICU and Intermediate level II of Alexandra was 17.22 and
24.16 days respectively. The mean LOS in the NICU and Inter-
mediate level II of A.Kyriakou was 8.5 and 11.5 days respec-
tively. CONCLUSION: Estimates of the economic costs of
preterm birth can be informative to decision-makers and facili-
tates quality improvement efforts used in neonatal care.
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OBJECTIVES: To establish a model that estimates a preference-
based measure of social participation for children between 8 and
18 years from the Handicap Scale for Children (HSC) classiﬁca-
tion system. METHODS: A sub-sample of the social participa-
tion vignettes of the HSC classiﬁcation system was valued on a
VAS scale by a representative sample of 249 persons of the
general Dutch population aged 18 years onwards. Several models
based on a full state (econometric) method were considered in
order to extrapolate the available valuations for the sub-sample
to all possible vignettes. RESULTS: The best ﬁtted model
assumes that the VAS scale and the scale of the ﬁve dimensions
of the HSC (mobility, physical, daily activities, social integration
and orientation) are linear, includes an interaction for mobility
with physical independence, orientation with mobility, physical
independence, daily activities and social integration, and
accounts for clustering by respondents. The measurement prop-
erties of the weighted scoring of the best ﬁtted model improves
upon models which assume an ordinal scale of the ﬁve dimen-
sions, do not include interactions and/or do not account for clus-
tering. The model that simply sums up the levels of each
dimension provides systematic errors for the preferences. CON-
CLUSIONS: We obtained a preference-based measure for social
participation for children between 8 and 18 years that can be
used for assessing need, for quality assurance and for evaluating
interventions on a group level aiming to increase social partici-
pation in children with chronic illnesses.
PIH4
WHAT METHODS OF ASSESSMENT AND MANAGEMENT OF
ELDERLY PEOPLE ARE COST EFFECTIVE
Davies LM1, Drummond M2
1University of Manchester, Manchester, Greater Manchester, UK;
2University of York,York, UK
OBJECTIVES: The primary objective was to determine the cost-
effectiveness acceptability of targeted (TA) versus universal
assessment (UA) and geriatric team (GM) versus primary care
(PC) management models. METHODS: The primary effective-
ness measure was life years gained (LYGs). The perspective was
societal. The primary analysis used a 3-year timeframe. Resource
use data and survival were collected within a multi-centre, cluster
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randomised trial of general practitioner practices. Patients were
over 74 years old, living in the community, in the UK. Costs and
outcomes were discounted (3.5% recommended UK rate).
Missing data for censored cases were imputed by survival analy-
sis. Missing data due to missing observations were imputed by
characteristic of patient. Data were adjusted for age, gender and
cluster randomisation. Costs and LYGs were bootstrapped. Net
beneﬁt statistics were estimated. Cost-effectiveness acceptabil-
ity analysis used willingness to pay thresholds (GBP0 to
GBP50000). Sensitivity analysis assessed the impact of structural
factors and assumptions. RESULTS: 109 GP practices were
assigned to (a) assessment method: UA = 55 (21,762 patients)
TA = 54 (21,457 patients); (b) management method: GM = 55
(22,216 patients); PC = 54 (21,003 patients). Preliminary analy-
sis indicated a net cost to TA (GBP296; 2.5–97.5 percentile
GBP140-GBP448 ) versus UA and a net saving to PC (-GBP41;
2.5–97.5 percentile -GBP192-GBP107) versus GM. LYGs were
TA (0.006; 2.5–97.5 percentile -0.006–0.19) and PC (0.016;
2.5–97.5 percentile 0.004–0.28). The probability of net beneﬁt
was 0–0.50 for TA across the willingness to pay thresholds. The
probability of net beneﬁt for PC was 0.70–1.00. Sensitivity
analysis indicated the results for targeted assessment, but not PC,
were sensitive to method of imputing missing data and time-
frame. CONCLUSIONS: The cost-effectiveness of targeted
assessment is uncertain. PC management appears cost effective
in the primary and sensitivity analyses. The small cost and effect
differences between strategies indicate cost-effective conﬁgura-
tion of services may be driven primarily by local considerations.
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OBJECTIVES: Analysis of participation on drug costs in seniors
in the Czech Republic in connection with seniors’ social status
(e.g. ﬁnancial, household conditions). METHODS: Quota-
sampled questionnaire-based interview with 450 respondents
visiting pharmacy; Ratio men: women approximately 1 :2; Age
60 years old and elder; 3 regions of the Czech Republic.
RESULTS: Most of respondents (60%) live in households with
their partners. Respondent’s income was retirement pension in
80%. Its average level was between 5001 and 7499CZK.
Respondents used together 1651 medicines on physician’s pre-
scription in last four weeks. Overall co-payment for medicines
was 31,944CZK, e.g. 70CZK per patient. Only 27% of respon-
dents used fully reimbursed products. Respondents used together
273 OTC drugs in value of 12,900CZK, e.g. 29CZK per patient.
Average respondents spent on medicines 100CZK in last four
weeks, e.g. between 2 and 1.3% of their income. There were
respondents, about 10%, searching for the level of co-payment
in several pharmacies and 8% of respondents, who had to refuse
dispensation of medicines due to co-payment. CONCLUSIONS:
Our study demonstrates that there are patients who may fail to
access medication due to co-payment. The ﬁnancial participation
on health care costs is generally low in the Czech Republic (8.6%
of total health expenditures) but there were differences in co-
payment levels in patients ranging from 1CZK to thousands
CZK. This might be caused by the absence of any instrument
limiting the individual ﬁnancial participation for example in 12-
month period as in Sweden. In our study co-payments were
lower in smaller communities where respondents reported better
communication between physicians and patients or physicians
and pharmacists.
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OBJECTIVES: Comparison of population health is a matter of
concern for national governments and for international agencies.
This paper reports on the analysis of data collected by in national
surveys conducted in Sweden (S) and England & Wales (EW)
using the same health status questionnaire, administered by post
during 2002 and 2003. METHODS: Data were collected from
1945 respondents in Sweden and 1001 in England & Wales.
Both datasets were weighted to be representative of their respec-
tive national populations. RESULTS: Age-standardised EQ-
5Dvas was systematically higher for men than for women in both
surveys, however this position is reversed for women aged 70+
in the EW survey. Differences in age/gender-standardised EQ-
5Dvas between the 2 national surveys were small (typically <5).
Despite this apparent convergence, the age-standardised rates of
reported problem on the 5 EQ-5D dimensions varied signiﬁ-
cantly both by gender and by survey. The rates of problem on
usual activities, for example, were 2.3% and 6.2% for men and
women aged 20–44 in the Swedish survey. The corresponding
rates in the EW survey were 12.1% and 13.1%. Within-survey
regression models were constructed using EQ-5Dvas as the
dependent variable and recoding the 5 dimensions to 0/1 dummy
variables (no problem/any problem). Both models appear to ﬁt
the data reasonably well (r2 > 0.450) with roughly equivalent
constants (87.9 and 89.5) however, the value decrements given
by the beta coefﬁcients indicate large differences in the impor-
tance associated with each dimension. The highest decrements in
the Swedish survey are for mobility (15.7) and pain/discomfort
(12.0). The highest decrements in the EW survey are for usual
activities (11.4) and anxiety/depression (9.5). CONCLUSION:
The study explores some possible causes of the differences (and
similarities) noted in the analysis and propose a series of stan-
dard tables for use in reporting data on comparative population
health.
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OBJECTIVE: Quality of life (QoL) evaluation allows to under-
stand people’s health state perception and to compare wellbeing
between different (sub)populations. No data with EQ-5D existed
for the Italian population. Our objective was to evaluate QoL 
of the Italian general population aged 40–79 years old.
METHODS: Data was collected from a population-based survey
of people aged 40–79 years. Subjects randomly sampled from
electronic General Practitioners (GP) lists, and accepting to par-
ticipate (16 individuals per GP, with random replacement in case
of refusal), underwent medical examination, blood sampling,
resource utilization interview, and ﬁlled in the EQ-5D. Partici-
pation of GP’s to the EQ-5D sub-study was voluntary. Results
are reported as comparing data of 5th, 6th, 7th and 8th age
decades. RESULTS: A total of 1956 individuals (50.0% males)
from 128 GP’s (approximately half of the invited GP’s partici-
